A Phase I Randomized, Placebo-Controlled, Single-Blind, Multiple-Dose, Dose-Escalation Clinical Study to Assess the Safety and Pharmacokinetics of SRT2379 in Normal Healthy Male Volunteers.
Phase of Trial: Phase I
Latest Information Update: 13 Jun 2017
At a glance
- Drugs SRT 2379 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Biomarker; Pharmacokinetics
- Sponsors GlaxoSmithKline
- 10 Jun 2017 Biomarkers information updated
- 03 Dec 2010 Ttrial location (Wales) identified as reported by ClinicalTrials.gov.
- 03 Dec 2010 Planned end date changed from 1 Jul 2010 to 1 Aug 2010 as reported by ClinicalTrials.gov.